Xarelto Lawsuit Update: New Developments in Phila. Mass Tort Litigation

BloodThinnerHelp.com reports today on two new developments in the Philadelphia Mass Tort Litigation.  Recently, two new case management orders, Case Management Order No. 5 and Case Management Order No. 6, were released.

Case Management Order No. 5 is a stipulated protective order which outlines how certain documents including emails, text messages, and instant messages, should be protected throughout the litigation process.  This order was released on May 19, 2015.

Case Management Order No. 6 orders that the temporary discovery stay that was outlined in case management order 1 on February 10 2015 is to be lifted and both parties should proceed with the discovery process as Case Management Order no. 6 dictates.  This order was released on July 7, 2015.  More detailed information on the Xarelto lawsuits can be found here.

Xarelto Victims Filing Lawsuits:

The Philadelphia Mass Tort litigation was established after a motion was made to consolidate the rising number of lawsuits that made similar allegations against the same defendants, in this case, the manufacturers of Xarelto, pharmaceutical conglomerates Bayer AG and Janssen Pharmaceuticals, a subdivision of Johnson&Johnson.  There are about 400 cases currently consolidated in this mass tort group and the number is expected to continue to rise as the pretrial litigation continues.  Consolidating these cases in a mass tort litigation will expedite the judicial process for all parties involved and save on judicial resources.  A mass tort group is different from a class action because although these cases are consolidated, they are still tried as individual cases.  For a list of the cases filed in the Mass Tort Group, click here.

Most of the lawsuits filed commonly allege that Xarelto usage has caused either themselves or a loved one severe, uncontrollable internal bleeding which has led to serious injury.  The lawsuits also allege that the manufacturers of Xarelto were aware of the true dangers that Xarelto presented and failed to adequately warn doctors and patients of these dangers.

Xarelto’s Dangerous Defect:

The lawsuits allege that the reason that Xarelto is especially dangerous is because the drug does not have a corresponding antidote to its anticoagulant effects.  This is different from the way that traditional blood thinners work, such as Warfarin.  If a patient taking Warfarin experiences an internal bleeding emergency, a doctor can administer vitamin K and the blood will clot again.  If a patient taking Xarelto experiences an internal bleeding emergency, there is no way to stop the bleeding short of extreme life-saving medical measures.  

“If the manufacturers of Xarelto were aware of the drug’s defects and put it to market anyway, they deserve to be brought to justice.” Xarelto attorney Marc Goldich said, “We strongly encourage anybody who feels they have been harmed by Xarelto usage to contact us immediately.”

For any questions regarding this press release or the pending Xarelto litigation, please contact Marc Goldich at (866) 425-8902.